Last week I sent you the FDA panel vote. Six peptides recommended for the compounding list, BPC-157 and KPV included, and half the brand owners I talk to read it as the tide turning.
Maybe it is, eventually. That vote still needs the HHS Secretary's signature and a full rulemaking before a single pharmacy can touch any of the six, and nobody has published a timeline for either step.
Meanwhile two state boards already published something that is in effect right now, and it will cost this industry more than the panel vote helps it. Almost nobody in this lane covered it.
What the boards said
On May 26 the Alabama Board of Medical Examiners published a notice with this line in it. "Under no circumstances is it permissible for a physician to compound, administer, or dispense a non-FDA approved or research grade peptide to a patient."
On August 19 the Mississippi State Board of Medical Licensure, the Mississippi Board of Nursing and the Mississippi Board of Pharmacy signed a joint statement. "Under no circumstances is it permissible for a healthcare provider to compound, administer, or dispense a non-FDA approved or research-grade peptide to a patient."
Read those two sentences again. One word changed. Physician became healthcare provider.
LumaLex reports South Carolina's Board of Medical Examiners put out its own version in August with the same prohibitions. I could not find that one posted on the board's own site, so treat it as reported rather than confirmed.
The copy-paste is the actual story
When a regulator writes something from scratch it takes a year. When boards pass a document between each other it takes a week, and the second state is easier than the first because somebody already did the legal work.
Alabama in May, Mississippi in August. That is a template in circulation. Assume the next three states are already drafting from it.
Why this hurts you more than an FDA letter
An FDA warning letter is expensive to produce. It takes an investigator, a review of one specific site, and a legal sign-off, and at the end of it one vendor is in trouble. Five letters in a month was a big month.
A board notice costs a board nothing. One document, published once, and every licensed provider in the state is on notice at the same time. It never touches your store. It makes every clinic that buys from you in that state liable for using what they bought.
You can be fully compliant, run a clean site with no bac water bundle and no calculator, and still watch your clinic revenue in a state go to zero in a month.
Both workarounds are dead
Both notices close the two doors people were using.
On consent forms, Alabama says "patient consent forms purporting to identify a product as 'research-grade' are ineffective." Mississippi says they "do not mitigate or eliminate a provider's professional or legal liability." If any part of your sales pitch to clinics is that the patient signs a research waiver, that argument is now named and dead in two states.
On delegation, both say a provider cannot get out of it by handing the purchase or the administration to a nurse practitioner, a midwife or a physician assistant. That closes the med-spa structure where the physician is a signature on a wall and somebody else does the buying.
What I would do this week
Pull your customer list and sort it into licensed providers and everybody else. Those are two different businesses now and they have two different risk curves.
For the provider half, find out which states they are in. Alabama and Mississippi customers are the ones to talk to first, and the conversation is better coming from you than from their board.
Stop building any part of your clinic pitch on consent forms. It was always thin and now it is named in writing.
Watch the boards, not just FDA. The FDA warning letter page is the one everybody refreshes. The state board notice pages are where this is actually moving, and there is no press release when one goes up.
If you want a second set of eyes on your site before a board or an investigator gets there, reply to this email with AUDIT and I will add you to the list. We got more requests than we planned for after the FDA issue so it is running behind, but everybody on the list gets one.